Fowler's solution

Fowler's solution consists of 1% potassium arsenite (KAsO2) in water and was first described and published as a potential treatment for malaria and syphilis in the late 1700s and was once also prescribed as a tonic.[1][2] Thomas Fowler (1736–1801) of Stafford, England, proposed the solution in 1786 as a substitute for a patent medicine, "tasteless ague drop". It was known at the time as "Liquor Arsenicalis". From 1865, Fowler's solution was a leukemia treatment.[2][3]

From 1905, inorganic arsenicals like Fowler's solution saw diminished use as attention turned to organic arsenicals, starting with Atoxyl.[4]

As inorganic arsenic compounds are notably toxic and carcinogenic—with side effects such as cirrhosis of the liver, idiopathic portal hypertension, urinary bladder cancer, and skin cancers—Fowler's solution fell from use. In 2001, however, the U.S. Food and Drug Administration (FDA) approved a drug of arsenic trioxide to treat acute promyelocytic leukaemia,[5] and interest in arsenic chemistry has returned.[6]

References

  1. ^ Ho, Derek; Lowenstein, Eve J. (2016). "Fowler's Solution and the Evolution of the Use of Arsenic in Modern Medicine". Skinmed. 14 (4): 287–289. ISSN 1540-9740. PMID 27784519.
  2. ^ a b Jolliffe, D. M. (1993). "A history of the use of arsenicals in man". Journal of the Royal Society of Medicine. 86 (5): 287–289. doi:10.1177/014107689308600515. PMC 1294007. PMID 8505753.
  3. ^ Doyle, Derek (2009). "Notoriety to respectability: a short history of arsenic prior to its present day use in haematology". British Journal of Haematology. 145 (3): 309–317. doi:10.1111/j.1365-2141.2009.07623.x. PMID 19298591. S2CID 6676910.
  4. ^ Gibaud, Stéphane; Jaouen, Gérard (2010). Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy. Topics in Organometallic Chemistry. Vol. 32. pp. 1–20. Bibcode:2010moc..book....1G. doi:10.1007/978-3-642-13185-1_1. ISBN 978-3-642-13184-4.
  5. ^ Zhu, J.; Chen, Z.; Lallemand-Breitenbach, V.; de Thé, H. (2002). "How acute promyelocytic leukaemia revived arsenic". Nature Reviews Cancer. 2 (9): 705–714. doi:10.1038/nrc887. PMID 12209159. S2CID 2815389.
  6. ^ Chen, S. J.; Zhou, G. B.; Zhang, X. W.; Mao, J. H.; de Thé, H.; Chen, Z. (2011). "From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia". Blood. 117 (24): 6425–6437. doi:10.1182/blood-2010-11-283598. PMC 3123014. PMID 21422471.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.